Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Calcif Tissue Int. 2021 Apr;108(4):496-511. doi: 10.1007/s00223-020-00786-0. Epub 2021 Feb 14.
Osteoporosis is a state of bone fragility with reduced skeletal resistance to trauma, and consequently increased risk of fracture. A wide range of conditions, including traditional risk factors, lifestyle choices, diseases and their treatments may contribute to bone fragility. It is therefore not surprising that the multi-morbid patient with chronic kidney disease (CKD) is at a particularly high risk. CKD is associated with reduced bone quantity, as well as impaired bone quality. Bone fragility in CKD is a composite of primary osteoporosis, accumulation of traditional and uremia-related risk factors, assaults brought on by systemic disease, and detrimental effects of drugs. Some risk factors are modifiable and represent potential targets for intervention. This review provides an overview of the heterogeneity of bone fragility in CKD.
骨质疏松症是一种骨骼脆弱的状态,骨骼对创伤的抵抗力降低,骨折的风险相应增加。多种情况,包括传统危险因素、生活方式选择、疾病及其治疗都可能导致骨骼脆弱。因此,患有慢性肾脏病 (CKD) 的多病患者面临着特别高的风险也就不足为奇了。CKD 与骨量减少以及骨质量受损有关。CKD 中的骨脆弱是原发性骨质疏松症、传统和尿毒症相关危险因素的积累、全身性疾病引起的冲击以及药物的有害影响的综合表现。一些危险因素是可以改变的,代表了干预的潜在目标。本综述概述了 CKD 中骨脆弱的异质性。